Incidence of Acute Kidney Injury in Patients Coinfected with HIV and Hepatitis C Virus Receiving Tenofovir Disoproxil Fumarate and Ledipasvir/Sofosbuvir in a Real-World, Urban, Ryan White Clinic
| Autor: | Manish Patel, Aley G. Kalapila, Jessica L. Michal, Saira Rab, Lesley Miller, Kirk Easley, Alison Kyle |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
Male
Sofosbuvir HIV Infections Pathogenesis urologic and male genital diseases chemistry.chemical_compound 0302 clinical medicine Risk Factors 030212 general & internal medicine education.field_of_study Coinfection Incidence Acute kidney injury Hepatitis C Acute Kidney Injury Middle Aged Infectious Diseases Reverse Transcriptase Inhibitors 030211 gastroenterology & hepatology Female medicine.drug Ledipasvir Adult medicine.medical_specialty Georgia Adolescent Immunology Population Antiviral Agents 03 medical and health sciences Young Adult Virology Internal medicine medicine Humans education Tenofovir Aged Retrospective Studies Fluorenes business.industry Retrospective cohort study Odds ratio Hepatitis C Chronic medicine.disease chemistry Benzimidazoles business Kidney disease |
| Popis: | Ledipasvir/sofosbuvir (LDV/SOF), an antiviral treatment for hepatitis C virus (HCV), and tenofovir disoproxil fumarate (TDF), an antiretroviral for treating human immunodeficiency virus (HIV), may be coadministered in patients coinfected with these viruses. A drug interaction between LDV and TDF could increase TDF-associated nephrotoxicity rates; however, there is minimal clinical evidence describing acute kidney injury (AKI) rates in this population. This study was conducted at a Ryan White-funded facility in Atlanta, Georgia, that cares for over 5,000 patients with AIDS. This retrospective cohort used chart review to assess occurrence of and risk factors for AKI in HIV/HCV-coinfected patients receiving LDV/SOF and antiretroviral therapy (ART). AKI rates were compared between TDF-containing and non-TDF-containing ART groups according to Kidney Disease Improving Global Outcomes (KDIGO) criteria. Additional evaluated risk factors for AKI included chronic kidney disease and use of boosted protease inhibitor-based ART. In the 117 included patients, the overall incidence of AKI was 27.3%. AKI occurred more frequently in the non-TDF group (13/86, 15.1% vs. 19/31, 61.3%, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|